Fortrea Holdings (FTRE) Non-Current Deferred Tax Liability (2022 - 2026)
Fortrea Holdings (FTRE) reported Non-Current Deferred Tax Liability of $92.3 million for Q1 2026, down 21.71% on a YoY basis from $117.9 million in Q1 2025, and down 5.43% quarter-over-quarter from $97.6 million in Q4 2025.
Fortrea Holdings (FTRE) Non-Current Deferred Tax Liability (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Non-Current Deferred Tax Liability for 5 years, with the latest figure at $92.3 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deferred Tax Liability fell 21.71% year-over-year to $92.3 million; the trailing twelve-month figure through Mar 2026 stood at $92.3 million (down 21.71% YoY), and the FY2025 full-year result was $97.6 million, down 19.8% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $92.3 million, down from $97.6 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $184.5 million in Q4 2022, with the low at $92.3 million in Q1 2026.
- Historically, Non-Current Deferred Tax Liability has averaged $134.7 million across 5 years, with a median of $126.9 million in 2024.
- Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability decreased 26.11% — and 2025, when it dropped 15.76%.
- Fortrea Holdings' Non-Current Deferred Tax Liability stood at $184.5 million in 2022, then dropped by 19.95% to $147.7 million in 2023, then fell by 17.6% to $121.7 million in 2024, then fell by 19.8% to $97.6 million in 2025, then declined by 5.43% to $92.3 million in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $92.3 million (Q1 2026), $97.6 million (Q4 2025), and $106.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.30 Mn |
| Mar 31, 2026 | 92.30 Mn |
| Dec 31, 2025 | 97.60 Mn |
| Dec 31, 2025 | 97.60 Mn |
| Sep 30, 2025 | 106.90 Mn |
| Sep 30, 2025 | 106.90 Mn |
| Jun 30, 2025 | 112.80 Mn |
| Jun 30, 2025 | 112.80 Mn |
| Mar 31, 2025 | 117.90 Mn |
| Mar 31, 2025 | 117.90 Mn |
| Dec 31, 2024 | 121.70 Mn |
| Dec 31, 2024 | 121.70 Mn |
| Sep 30, 2024 | 126.90 Mn |
| Sep 30, 2024 | 126.90 Mn |
| Jun 30, 2024 | 136.10 Mn |
| Jun 30, 2024 | 136.10 Mn |
| Mar 31, 2024 | 150.70 Mn |
| Mar 31, 2024 | 150.70 Mn |
| Dec 31, 2023 | 147.70 Mn |
| Dec 31, 2023 | 147.70 Mn |